Nathalie Breysse, PhD, is a neuroscientist who earned her PhD in from the University of Luminy in France. Her studies were related to the functional involvement of metabotropic glutamate receptors within the basal ganglia circuitry in normal and pathological conditions. Dr. Breysse’s original research gave rise to manuscripts on the potential of mGluR5 receptors as a therapeutic target in treating Parkinson’s disease. She then joined the Wallenberg Neuroscience Center (Lund, Sweden) as a postdoctoral fellow under Prof. Anders Bjorklund’s mentorship. Her work focused on the use of cell- and gene therapy in the treatment of Parkinson’s disease.

In the last 10 years, Dr. Breysse has worked in the pharmaceutical industry at NPS Pharmaceuticals (Canada), Wyeth/Pfizer (United States) and Lundbeck (United States and Denmark), in drug discovery and development programs related to neuropsychiatric as well as neurodegenerative disorders. She is currently the global Parkinson’s disease therapeutic biology lead at Lundbeck.